Chronic Hypertension in Pregnancy
Admission & discharge
Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.
When admission or continued hospital care is needed
- Severe-range BP (systolic ≥160 or diastolic ≥110 mmHg), symptoms suggesting superimposed pre-eclampsia, concerning blood tests or fetal compromise need hospital assessment; admit when surveillance/treatment cannot be delivered safely outside hospital.
When clinic, day care or home care may be suitable
- Stable treated chronic hypertension can be followed in clinic with a recorded maternal/fetal surveillance plan.
Before going home
- Severe BP has resolved on an established oral plan; symptoms, renal/liver/platelet results and fetal assessment have been reviewed.
- After birth, BP and medicine review must be arranged before leaving; a single normal reading is insufficient after recent severe hypertension.
Discharge medicines and treatment changes
- Continue the selected maintenance medicine with a written dose and adjustment plan. Stop methyldopa within 2 days after birth and substitute if needed; do not automatically stop every antihypertensive.
- Check breastfeeding compatibility and renal function/potassium for postpartum enalapril; it is not an antenatal medicine.
Medicine doses — use only when indicated
Use the medicines selected for this patient. Listed alternatives are not instructions to prescribe all of them together. Confirm the actual remaining course, pregnancy/postnatal context and monitoring plan.
A selected maintenance option when prescribed.
- Indication: Maintenance hypertension during pregnancy/postpartum
- BP/heart rate, postural symptoms; neonatal glucose/heart-rate observation after late-pregnancy exposure
An alternative maintenance option; use the modified-release formulation specified.
- Indication: Maintenance hypertension in pregnancy/postpartum
- BP, headache, flushing, oedema and pulse
Tests, pending results and their reviewer
- Document baseline/recent creatinine, urine protein and other tests indicated by the presentation; schedule follow-up for any abnormality.
Home care and counselling
- Give a written BP-monitoring schedule, thresholds for contacting the unit and named responsibility for prescription changes.
Follow-up: when and what to review
| When | Action / responsible service |
|---|---|
After birth: first 2 days and day 3–5 | Arrange BP measurement; continue the individual monitoring schedule if abnormal. |
2 weeks / 6–8 weeks after birth | Review antihypertensive treatment at 2 weeks; review longer-term BP and cardiovascular/renal care at 6–8 weeks. |
Return urgently
- Severe headache, visual change, epigastric/right-upper-quadrant pain, chest pain, breathlessness or a severe BP reading require urgent reassessment.
Open the complete discharge checklist →
Treatment
① Immediate stabilization — first minutes
- If SBP ≥160/DBP ≥110: manage as hypertensive emergency (see hdp-severe-features / Emergency Hub — Acute Severe Hypertension)
- Otherwise: confirm diagnosis, stop teratogens (ACEi/ARB), start lifestyle advice + pharmacotherapy threshold discussion
② Assessment & investigations
- Booking panel as above
- Home BP monitoring if white-coat suspected (ISSHP rec 9)
③ First-line treatment & drug regimens
First-line oral agents (all major guidelines concordant): labetalol, extended-release nifedipine, or methyldopa.
- Maintenance hypertension during pregnancy/postpartum
- BP/heart rate, postural symptoms; neonatal glucose/heart-rate observation after late-pregnancy exposure
- Maintenance hypertension in pregnancy/postpartum
- BP, headache, flushing, oedema and pulse
- Maintenance hypertension during pregnancy; not emergency BP rescue
- Postpartum stopping recommendation: NICE NG133.
- BP, sedation/mood; blood count and LFTs for fever, jaundice or suspected toxicity
- Second line: hydralazine, clonidine, prazosin; amlodipine has growing safety data
- Thiazides: CONTINUE only if already established pre-conception and BP controlled; do not start de novo (plasma-volume contraction, oligohydramnios concerns)
- Atenolol: AVOID (fetal growth restriction)
④ Drug treatment detail (1 agents)
- Indication: NICE regimen for pre-eclampsia prevention in women meeting high/moderate-risk criteria
- Some other named prevention protocols stop at 36 weeks. Choose and document one start/stop protocol rather than prescribing a fixed number of weeks irrespective of gestation.
- Adherence, bleeding, allergy and the evolving obstetric risk assessment
Non-drug treatment
- Weight management per IOM gain limits; moderate exercise ≥150 min/wk (reduces HDP risk 30–40%)
- No routine salt restriction in pregnancy except established chronic HTN context
- Assess dietary calcium; the WHO low-intake-population regimen is 1.5–2 g elemental calcium/day in three divided doses, with iron separated. See the complete antenatal supplementation card.
Definitive treatment
Delivery resolves the physiological driver but NOT necessarily chronic hypertension — plan timed birth ~38–39 weeks if controlled (individualise earlier if superimposed disease).
Monitoring
| What | Frequency |
|---|---|
Home/clinic BP | Weekly (or HBPM daily log) once stable; twice-weekly if titrating |
CBC+platelets, LFT, creatinine | Every 4 weeks (monthly) — more often if rising trend |
Urine protein | At booking, then if symptoms/BP rise |
Fetal growth (EFW/AC) + Doppler as indicated | From 28–32 wks every 3–4 weeks if risk factors |
Response assessment
- Target achieved without symptomatic hypotension
- No emergence of proteinuria/organ dysfunction
- Normal fetal growth trajectory
Treatment failure
- BP above target despite max oral monotherapy → add second agent
- Emergence of proteinuria/end-organ signs → manage as superimposed pre-eclampsia
Second-line treatment
- Combination labetalol + nifedipine ER (or + methyldopa)
- Refer to obstetric-medicine/cardiology if resistant
Procedure / surgery
Mode/timing of birth: planned vaginal birth usual; caesarean only for obstetric indications. Induction ~38–39 wks for well-controlled chronic HTN (NICE); individualise with comorbidities.
Escalation
- Severe-range BP → HDU-level monitoring same visit
- Suspected superimposed PE → hospital assessment
- End-organ involvement → tertiary centre with NICU
⑮ Complications & their management
Superimposed pre-eclampsia
See hdp-severe-features; aspirin does not treat established disease
Placental abruption (risk ↑)
See aph-abruption pathway
FGR
Serial growth + Doppler surveillance per fgr module
Post-treatment care
- Postpartum: resume/continue compatible agents (labetalol/nifedipine/enalapril OK breastfeeding)
- Review at 2 weeks and 6 weeks postpartum
- Lifetime cardiovascular risk counselling — annual review ×5–10 years (ISSHP)
- Pre-conception planning next pregnancy: stop ACEi/ARB, start folic acid, aspirin prophylaxis plan
Diagnosis & assessment
- New proteinuria or organ dysfunction after 20 wks → superimposed pre-eclampsia
- SBP ≥160/DBP ≥110 → emergency
- Reduced fetal growth/movement
- Symptoms: headache, visual changes, epigastric pain, brisk reflexes
Definition: Known hypertension before pregnancy OR BP ≥140/90 mmHg confirmed before 20 weeks gestation, persisting beyond the puerperium (FOGSI GCPR 2026 §3.1; exclude trophoblastic disease/molar pregnancy and multifetal gestation as causes of early BP rise).
Risk factors
Presentation
- Often asymptomatic — detected at booking visit
- May present with headache/dizziness if BP high
- Superimposed pre-eclampsia declared by new proteinuria/end-organ features after 20 wks
Initial assessment
- Confirm BP: validated device, sitting position, correct cuff size (large cuff if mid-arm ≥33 cm), Korotkoff V for DBP (ISSHP standard technique)
- If SBP ≥160/DBP ≥110 → recheck within 15 minutes and treat urgently (do not wait hours)
- Baseline labs: CBC + platelets, creatinine/eGFR, LFTs, urate, urine protein quantification (PrCr/ACR/24h), TSH if indicated
- Assess end-organ history: previous hypertensive complications, current medications (STOP teratogenic antihypertensives — ACE inhibitors/ARBs immediately)
- Fetal assessment: dating viability scan, growth surveillance plan
Investigations
| Test | Looking for |
|---|---|
Creatinine (+ eGFR), electrolytes | Baseline renal function; CKD coexistence raises risk |
CBC + platelets, LFTs, urate | Baseline to detect later superimposed pre-eclampsia trends |
Spot urine PrCr/ACR or 24h protein | Baseline proteinuria (persistent baseline proteinuria predicts worse outcomes) |
Renal/bladder US ± secondary-cause screen only if clues exist | Secondary hypertension workup NOT routine (ISSHP rec 8) |
Algorithm
Principles & follow-up
Management principles
Guideline conflict
FOGSI–GESTOSIS–ICOG GCPR 2026 (WOG position)
Treat all HDP including chronic HTN from BP ≥140/90; targets systolic ≤140, diastolic ≤90
NICE NG133 (UK) / ACOG PB222+CHAP advisory
ACOG: initiate/titrate therapy at ≥140/90 (treatment threshold, not goal); NICE: treat ≥140/90 with target ≤135/85
Population/setting difference: CHAP trial (n=2408) showed treating mild chronic HTN at 140/90 reduced severe outcomes without increasing SGA — driven largely by a US/low-risk cohort
Practical India consideration: Indian women have higher background pre-eclampsia/eclampsia burden (NER data) and often present late; a lower treatment threshold with close supervision is pragmatic
Reason: Concordant across FOGSI 2026, ISSHP 2021, ACOG advisory 2022 and ESC 2024 — no practical disagreement remains for chronic HTN
Follow-up
- 2-week postpartum BP review
- 6-week complete review incl. meds optimisation for lifelong control
- Annual BP/CV risk review
Patient education
- Self-monitoring BP diary
- Danger signs requiring same-day contact: severe headache, visual disturbance, epigastric pain, reduced fetal movements, swelling face/hands with symptoms
Sources (13)
2026-01 · checked 2026-08-23 · verified-live
Open source ↗
PDF served from fogsi.org (2026 upload path) — definitions, HDP-Gestosis score, treatment threshold ≥140/90 (WOG), targets ≤140/90, delivery timing (GH term; mild PE 37 wks; severe PE after 34 wks; eclampsia deliver once stabilised post-MgSO4; ≤24 wks immediate delivery better; individualise 24–33+6…
2021 (publ 2022 Hypertension) · checked 2026-08-23 · verified-live
Open source ↗
Full PDF: standardised BP measurement; proteinuria PrCr ≥30 mg/mmol, ACR ≥8 mg/mmol or ≥300 mg/day or dipstick 2+ if confirmatory testing unavailable; no 'mild/severe' PE label in ongoing pregnancy; treat all HDP with antihypertensives; severe HTN ≥160/110 treat within minutes-hours monitored; targe…
2022-04 · checked 2026-08-23 · verified-summary
Open source ↗
Publisher summary + independent 2025 review confirming advisory remains operative: initiate/titrate therapy at ≥140/90 mmHg for chronic HTN (treatment threshold, not target). Note ACOG PB222 base document last reaffirmed — verify current reaffirmation date when next audited.
2024 · checked 2026-08-23 · verified-summary
Open source ↗
Independent peer-reviewed comparison table (Clin Hypertens 2025): initiate drugs ≥140/90; targets SBP <140, DBP 80–90
· checked 2026-10-17 · verified-live
Open source ↗
100 mg twice daily with increments, divided higher dosing, 2400 mg/day limit and beta-blocker cautions.
· checked 2026-10-17 · verified-live
Open source ↗
Scanned primary PDF pages 103–104 examined by OCR and visual review: labetalol prose sequence/cumulative 300 mg, sustained-release nifedipine 10 mg twice daily/max 80 mg, and internal prose/flowchart differences for acute nifedipine and labetalol. The app exposes rather than merges the differences.
· checked 2026-10-17 · verified-live
Open source ↗
250 mg twice/three times daily, slow increments, 3 g/day maximum, hepatic/depression cautions. NICE NG133 supplies the separate postpartum stopping recommendation.
25 June 2019 · updated 17 April 2023 · checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for hdp-postpartum. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Targeted medication audit: Table…
· checked 2026-10-18 · verified-live
Open source ↗
Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.
· checked 2026-10-18 · verified-live
Open source ↗
Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.
· checked 2026-10-18 · verified-live
Open source ↗
Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.
· checked 2026-10-18 · verified-live
Open source ↗
Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge…
· checked 2026-10-18 · verified-live
Open source ↗
Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.